

FORM PTO-139 (Modified) (Rev. 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 1038-1030 MIS:jb	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/554333	
				PRIORITY DATE CLAIMED 14 November 1997	
INTERNATIONAL APPLICATION NO. PCT/CA98/01065		INTERNATIONAL FILING DATE 13 November 1998			
TITLE OF INVENTION ALPHAVIRUS VECTORS					
APPLICANT(S) FOR DO/EO/US Mark Parrington, and Michel H. Klein					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). - unsigned copy 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 					
<p>Items 13 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> Certificate of Mailing by Express Mail 20. <input type="checkbox"/> Other items or information: 					

U.S. APPLICATION NO. (IF KNOWN SEE 37 CFR

09/554333

INTERNATIONAL APPLICATION NO.

PCT/CA98/01065

ATTORNEY'S DOCKET NUMBER

1038-1030 MIS:jb

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☒ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$970.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	14 - 20 =	0	x \$18 00	\$0.00
Independent claims	2 - 3 =	0	x \$78 00	\$0.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS =				\$970.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

☐

\$0.00

SUBTOTAL =

\$970.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$970.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☐

\$0.00

TOTAL FEES ENCLOSED =

\$970.00

Amount to be:
refunded \$
charged \$

- ☒ A check in the amount of \$970.00 to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **19-2253** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mr. Michael I. Stewart
Sim & McBurney
6th Floor, 330 University Avenue
Toronto, Ontario
Canada, M5G 1R7

SIGNATURE

Michael I. Stewart

NAME

24,973

REGISTRATION NUMBER

May 11, 2000

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Our Ref: 1038-1030 MIS:jb

In re National Phase of International
Application No.: PCT/CA98/01065
International Filing Date: 13 November 1998
Applicant: Mark Parrington, et al.
Title: ALPHAVIRUS VECTORS

PRELIMINARY AMENDMENT

The Commissioner of Patents
and Trademarks,
Washington, D.C. 20231,
U. S. A.

Dear Sir:

Please amend this application in the following manner:

In the Disclosure:

Before the first line of the specification, add the following:


" REFERENCE TO RELATED APPLICATIONS

This application is a national phase application under 35 U.S.C. 371 of
PCT/CA98/01065."

REMARKS

The specification has been amended on page 1 to reflect that this
application is a U.S. National Phase filing under 35 U.S.C. 371 of PCT/CA98/01065.

Respectfully submitted,



Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada
(416) 595-1155
FAX No. (416) 595-1163

Date: May 11, 2000

TITLE OF INVENTIONALPHAVIRUS VECTORSFIELD OF INVENTION

The present invention relates to the field of DNA vaccines and is particularly concerned with modified alpha virus vectors for use in such vaccines.

BACKGROUND OF THE INVENTION

10 Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA
15 can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized
20 they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 1 - Throughout this application,
25 various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification. The disclosures of these references are hereby incorporated
30 by reference into the present disclosure). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural

proteins. In 1991 Liljestrom and Garoff (ref. 2) designed a series of expression vectors based on the SFV CDNA replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex. Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV CDNA for linearization of the plasmid for use *in vitro* transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a number of studies (refs. 3,4). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed *in vivo* the protein should have the same conformation as the protein expressed by the virus itself. Therefore, concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

In WO95/27044, the disclosure of which is incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transceprional control of a heterologous promoter, the alphavirus RNA is able to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

10

SUMMARY OF THE INVENTION

The present invention is concerned with modifications to the alphavirus cDNA vectors described in the aforementioned WO 95/27044 to permit enhanced replication of the alphavirus. In the present invention, a heterologous splice site is introduced into the alphavirus replicon sequence, particularly that of Semliki Forest virus (SFV).

Accordingly, in one aspect, the present invention provides an expression vector comprising a DNA molecule complementary to at least part of an alphavirus RNA genome, which DNA molecule comprises the complement of the complete alphavirus RNA genome regions which are essential for replication of the said alphavirus RNA, and further comprises a heterologous DNA sequence capable of expression in a suitable host, such as a human or animal host, said heterologous DNA sequence being inserted into a region of the DNA molecule which is non-essential to replication thereof, and the DNA molecule being placed under transcriptional control of a promoter sequence functional in said animal or human host, wherein at least one heterologous splice site is

provided in the DNA molecule to prevent aberrant RNA splicing of the alphavirus.

The alphavirus molecule is a large molecule and, accordingly, there is a high probability of cryptic splice sites, thereby impairing the replication of the alphavirus and hence its ability to express the heterologous DNA is impaired. By introducing the at least one optimal heterologous splice site in accordance with the present invention into the alphavirus replicon sequence, any splicing is likely to be directed at the heterologous splice site rather than any cryptic splice sites, restores the function of the SFV replicon when removed, and may improve transport of RNA from the nucleus (ref. 6).

In the constructs provided herein, the promoter is placed upstream of the 5'-end of the alphavirus sequence, such that the resultant transcript has an authentic 5'-end, which is required for the efficient replication of the alphavirus RNA replicon.

In addition, there may be provided at the 3'-end of the Semliki Forest virus segment, a hepatitis delta virus ribozyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the sequence. Any other convenient sequence may be employed to achieve this effect.

The heterologous splice site sequence may be provided by the nucleotide sequence of the rabbit β -globin intron II, as described in reference 5. Such heterologous splice site sequence may be inserted into the complement sequence at any convenient location which generates perfect splice junctions. This

precludes replication of the alphavirus, unless it is authentically removed by splicing..

I have identified five suitable sites in the SFV replicon, which are contained within an EcoRV-SpeI
5 fragment of the replicon which is 8010 bp in length (Fig. 3). The first such site is a Ppu-MI site, at position 2719 within the EcoRV-SpeI fragment.

In constructing the modified vectors provided herein, the EcoRV-SpeI fragment is cut with Ppu-MI at
10 position 2719 and made blunt-ended with Mung Bean nuclease, which removes three bases from the SFV sequence. A blunt-ended β -globin II intron, which is 536 bp long, is ligated into the site and replaces the missing three bases with sequence added to the 3'-end
15 of the β -globin intron sequence (Fig. 1).

The other four suitable sites for insertion of the Intron are the PvuII sites at bp 2518, 3113, 6498 and 6872 of the EcoRV-SpeI fragment. Insertion of the Intron is achieved by cutting with PvuII (a blunt end
20 cutter) and the blunt-ended β -globin II intron sequence (Fig. 2) is ligated into one or more of these sites.

In a further aspect of the present invention, there is provided a cloning vector suitable for expression in a host cell of an heterologous DNA
25 sequence, which comprises a DNA molecule complementing to at least part of an alphavirus RNA genome, which DNA molecule comprises the complement of the complete alphavirus RNA genome regions and has a cloning site for insertion therein of a heterologous DNA sequence
30 capable of expression in a host cell, said cloning site being located in a region of the DNA molecule which is

non-essential to replication thereof; a promoter sequence functional in said host cell and transcriptionally controlling said DNA molecule, said promoter sequence being placed upstream of the 5'-end of the DNA molecule such that the resultant transcript had an authentic 5' end; at least one heterologous splice set provided in the complement of the DNA molecule to generate perfect splice junctions in the alphavirus in order to prevent aberrant splicing and an additional DNA sequence at the 3'-end of the DNA molecule to direct proper *in vivo* cleavage at the 3'-end of the reactant mRNA transcript.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows the DNA sequence of the β -globin intron II including three additional nucleotides at the 3'-end thereof (SEQ ID No:1);

Figure 2 shows the DNA sequence of the β -globin intron II (SEQ ID No:2);

Figures 3A to 3C show the DNA sequence of the EcoRV-SpeI fragment of Semliki Forest virus replicon (SEQ ID No:3);

Figures 4A to 4D show the DNA sequence of the pSFV link (SEQ ID no: 4) prepared as illustrated in Figure 5;

Figure 5 shows construction of pSFVlink (11060 bp) from pSFV1 using a linker sequence (SEQ ID nos: 5,6);

Figures 6A to 6D show the nucleotide sequence of plasmid pMP76 (SEQ ID no: 11, prepared as illustrated in Figures 8A to 8D);

Figure 7 illustrates subsections of plasmid pSFV link (see Figure 5);

Figure 8A to 8D show the construction of plasmid pMP76 from plasmids pMP53, pMP70, pMP47, pMP55 and pMP71;

Figures 9A to 9B show the construction of plasmids
5 pMP53, pMP54 and pMP55 from plasmid pMP52;

Figure 10 shows the construction of plasmid MP52 from pUC19 using a linker sequence (SEQ ID no: 7,8);

Figures 11A to 11B show the construction of plasmids pMP46, pMP47 and pMP70 from pUC19 and fragment
10 from pSFV link, prepared as seen in Figure 7; and

Figures 12A to 12B show the construction of plasmid pMP71 from plasmid pCMV3.

GENERAL DESCRIPTION OF INVENTION

15 As discussed above, the present invention provides a modified alphavirus DNA. The alphavirus preferably is Semliki Forest virus. In particular, the present invention provides a cloning vector for heterologous gene expression in a host, such as an animal or human.

20 The promoter sequence may comprise a promoter of eukaryotic or prokaryotic origin. Suitable promoters are the cytomegalovirus immediate early promoter (pCMV), although other promoters, such as the Rous sarcoma virus long-terminal repeat promoter (pRSV),
25 since, in the case of these and similar promoters, transcription is performed by the DNA-dependent RNA polymerase of the host cell. Additionally, the SP6, T3 or T7 promoters can be used, provided that the cell has first been transformed with genes encoding SP6, T3 or
30 T7 RNA polymerase molecules which are either inserted into the chromosome or remain episomal. Expression of

these (SP6, T3, T7) RNA polymerase-encoding genes is dependent on the host cell DNA-dependent RNA polymerase.

The heterologous DNA insert may comprise the coding sequence for a desired product, which may be a biologically active protein or polypeptide, for example, the heterologous DNA insert may code for HIV sequences, e.g., an immunogenic or antigenic protein or polypeptide, or a therapeutically active protein or polypeptide. The heterologous DNA may also comprise additional sequences, such as a sequence complementary to an RNA sequence which is a self-cleaving ribozyme sequence.

The DNA vectors provided herein may be administered to a host, including a human host, for *in vivo* expression of the heterologous DNA sequence, in accordance with a further aspect of the invention, in order to generate an immune response in the host, which may be a protective immune response. The DNA vectors may be further formulated into immunogenic compositions for such administration.

BIOLOGICAL DEPOSITS

Certain vectors that contain the Semliki Forest virus replicon and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based

upon this United States patent application and all restrictions on access to the deposits will be removed at that time. Non-viable deposits will be replaced. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention.

Deposit Summary

<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
pMP76		

EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

EXAMPLE 1

This Example describes the construction of plasmid pMP76 as outlined in Figures 5, 7, 8A, 8B, 8C, 8D, 9A, 9B, 10, 11A, 11B, 12A and 12B.

- 5 Plasmid pSFV link was created by restricting plasmid pSFV1 (Gibco) with BamHI. This plasmid was then ligated with a linker (SEQ ID no: 5 and 6) to produce plasmid pSFV link (Figures 4A to 4D, Figure 5).

- Some of the SFV replicon fragments were subcloned
10 by restricting pSFVlink with EcoRV and SpeI and isolating the 890bp EcoRV-SpeI fragment. This fragment was then restricted with EcoRI and the 1906bp EcoRV-EcoRI, the 1578bp and 3627bp EcoRI-EcoRI and the 899bp EcoRI-SpeI fragments isolated (Fig.7).

- 15 The 1909bp EcoRV-EcoRI SFV fragment was cloned into EcoRV-EcoRI restricted plasmid pMP52 to produce plasmid pMP53 (Fig.9A). The 899bp EcoRI-SpeI SFV fragment was cloned into EcoRI-SpeI restricted pMP52 to produce pMP54 (Fig.9A). Plasmid pMP54 was then
20 restricted with SpeI and made blunt-ended with Mung Bean nuclease. The plasmid was then restricted with BglII, dephosphorylated and ligated to the hepatitis delta virus ribozyme linker (SEQ ID nos. 9 and 10), that had been phosphorylated, to produce pMP55 (Fig.
25 9B).

Plasmid pMP52 was created by ligating a linker (SEQ ID nos:7,8), into the EcoRI site of pUC19 (Fig.10).

- The 1578bp EcoRI-SFV fragment was cloned into
30 the EcoRI site of pUC19, to produce pMP46 (Fig.11A). This plasmid was then restricted with PpuMI and made

11

blunt-ended with Mung Bean nuclease. The rabbit β -globin intron II PCR fragment (Fig.1) was made blunt-ended with Mung Bean nuclease, phosphorylated and ligated to the PpuMI restricted pMP46 to produce
5 plasmid pMP70 (Fig.11B).

The 3627bp EcoRI SFV fragment was cloned into the EcoRI site of pUC19 to produce pMP47 (Fig.11A).

Plasmid pCMV3, which contains the CMV promoter, Intron A sequence, BGH poly A sequence and
10 SU40 poly A sequence, was restricted with NdeI and EcoRV. The 3191bp NdeI-EcoRV fragment was isolated and dephosphorylated. The 1321bp NdeI-EcoRV fragment was isolated and restricted with SacI. The NdeI-SacI fragment of 334bp was isolated (Fig.12A). The isolated
15 SacI-EcoRV PCR fragment containing the 5'-end of SFV was ligated to the previously isolated 334bp NdeI-SacI fragment and the 3191bp NdeI-EcoRV fragment to produce pMP71 (Fig.12A and 12B).

Plasmid pMP53 was then restricted with EcoRI
20 and BamHI and ligated to the isolated and dephosphorylated 2151bp EcoRI fragment from pMP70 (Fig.8A). This ligation was then restricted with EcoRV and the 4057bp EcoRV-EcoRI fragment purified (Fig.8A).

Plasmid pMP47 was restricted with EcoRI and
25 the 3627bp EcoRI fragment isolated and dephosphorylated (Fig.8B). Plasmid pMP55 was then restricted with BglII, dephosphorylated and restricted with EcoRI. The 985bp EcoRI-BglII fragment was isolated and ligated to the previously isolated EcoRI fragment from pMP47
30 (Fig.8B). The ligation reaction was then

12

phosphorylated and the 4612bp EcoRI-BglII fragment isolated.

Plasmid pMP71 was restricted with EcoRV and BamHI then dephosphorylated. This fragment was used in a 3-way ligation with the previously isolated 4612bp EcoRI-BglII fragment from pMP47 and pMP55, and the 4057bp EcoRV-EcoRI fragment from pMP53 and pMP70, to produce pMP76 (Figs.8B and 8C).

The 5' end of the SFV replicon was produced by PCR amplification of pSFV1 using primers SFV-5'-3' having the sequence

5'-ATCTATGAGCTCGTTTAGTGAACCGTATGGCGGATGTGTGACATACA-3' and EcoR-SPE having the sequence

5'-TCCACCTCCAAGGATATCCAAGATGAGTGTG-3' (SEQ ID no: 9 and SEQ ID no: 10 respectively) between the CMV promoter and the 5' end of the SFV replicon. The resulting PCR fragment was restricted with SacI and EcoRV (Fig. 13; SEQ ID no: 11) and the fragment isolated.

SUMMARY OF DISCLOSURE

In summary of this disclosure, the present invention provides a modified alphavirus-based expression vector wherein at least one optimal splice site is introduced to the alphavirus replicon to prevent aberrant splicing of the alphavirus genome; and improve transport of RNA out of the nucleus. Modifications are possible within the scope of the invention.

REFERENCES

1. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G., (1969) Am. J. Epidemiol. 89 (4), 435-448.
- 5 2. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
- 10 3. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) J. Immunol. 89, 216-226.
4. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmstead, R.A., Spriggs, M.K.,
15 Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.N. (1988) Vir. Res. 11, 1-15.
5. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-
20 3986.
6. Huang, Zhi-ming and Yen, T. S. Benedict, Molecular and Cell Biology, July 1995, p.3864-3869.

CLAIMS

1. An expression vector, comprising a DNA molecule complementary to at least part of an alphavirus RNA genome, which DNA molecule comprises the complement of the complete alphavirus RNA genome regions which are essential for replication of the said alphavirus RNA and further comprises a heterologous DNA sequence capable of expression in a host, said heterologous DNA sequence being inserted into a region of the DNA molecule which is non-essential to replication thereof, and the DNA molecule being placed under transcriptional control of a promoter sequence functional in said host, wherein at least one heterologous splice site is provided in the DNA molecule to prevent aberrant RNA splicing of the alphavirus.
2. The vector of claim 1 wherein said promoter is placed upstream of the 5'-end of the DNA molecule such that the resultant transcript has an authentic 5'-end.
3. The vector of claim 2 wherein said promoter is the cytomegalovirus immediate early promoter.
4. The vector of claim 1 which further comprises an additional DNA sequence at the 3'-end of the DNA molecule to direct proper *in vivo* cleavage at the 3'-end of the DNA molecule.
5. The vector of claim 4 wherein said additional DNA sequence comprises a hepatitis delta ribozyme sequence.
6. The vector of claim 1 wherein the heterologous splice site sequence is provided by the DNA sequence of the rabbit β -globin intron II.
7. The vector of claim 6 wherein the heterologous splice site sequence is inserted into the DNA molecule

at a location which generates perfect splice junctions and restores the function of the SFV replicon when removed.

8. The vector of claim 1 wherein the alphavirus is a
5 Simliki Forest virus.

9. A cloning vector suitable for expression in a host cell of an heterologous DNA sequence, which comprises:

a DNA molecule complementing to at least part of an alphavirus RNA genome, which DNA molecule comprises
10 the complement of the complete alphavirus RNA genome regions and has a cloning site for insertion therein of a heterologous DNA sequence capable of expression in a host cell, said cloning site being located in a region of the DNA molecule which is non-essential to
15 replication thereof;

a promoter sequence functional in said host cell and transcriptionally controlling said DNA molecule, said promoter sequence being placed upstream of the 5'-end of the DNA molecule such that the resultant
20 transcript had an authentic 5' end;

at least one heterologous splice set provided in the complement of the DNA molecule to permit aberrant RNA splicing of one to generate perfect splice junctions in the alphavirus; and

25 an additional DNA sequence at the 3'-end of the DNA molecule to direct proper *in vivo* cleavage at the 3'-end of the reactant RNA molecule.

10. The cloning vector of claim 9 wherein said heterologous splice set is provided by the DNA sequence
30 of the rabbit β -globin intron II.

11. The cloning vector of claim 9 wherein said additional sequence comprises a hepatitis delta ribozyme sequence.
12. The cloning vector of claim 8 wherein the
5 alphavirus is a Semliki Forest virus.
13. The cloning vector of claim 8 which has the identifying characteristics of plasmid pMP76 shown in Figure 8D.
14. The cloning vector of claim 8 having SEQ ID no:
10 11.

FIG.1

Nucleotide Sequence of the β -globin intron II with the 3' SFV bases

gtgagtttgg	ggaccottga	ttgttcttc	tttttcgcta	ttgtaaaatt	catgttatat	60
ggagggggca	aagttttcag	ggtgttggtt	agaaatggga	gatgtccctt	gatacccat	120
ggaccctcat	gataattttg	tttctttcac	ttctactct	gttgacaacc	attgtctcct	180
cttattttct	tttcattttc	tgtaaacttt	tcgttaaact	ttagcttgca	tttgtaacga	240
atttttaaat	tcacttttgt	ttatttgta	gattgtaagt	actttctcta	atcacctttt	300
tttcaaggca	atcagggtat	attatatgt	acttcagcac	agtttttagag	aacaattgtt	360
ataattaaat	gataaggtag	aatatattctg	catataaat	ctggctggcg	tggaatatatt	420
cttatatggta	gaaacaacta	catcctggtc	atcatcctgc	ctttctcttt	atggttacaa	480
tgatatacac	tgtttgagat	gaggataaaa	tactctgagt	ccaaacgggg	cccctctgct	540
aaccatgttc	atgccttctt	ctttttccta	caggtc			576

FIG.2

Nucleotide Sequence of the β -globin intron II

gtgagtttgg ggacccttga ttgttctttc tttttcgcta ttgtaaaatt catgttatat 60
 ggagggggca aagtttttcag ggtgttgttt agaattggga gatgtccctt gatatcccat 120
 ggaccctcat gataattttg ttcttttcac ttctactctt gttgacaacc attgtctcct 180
 ctatttttct ttccattttc tgtaactttt tggtaaaact ttagcttgca ttgtaacga 240
 atttttaaat tcacttttgt ttatttgtca gattgtaagt actttctcta atcacttttt 300
 ttccaaggca atcagggtat attatatgt acttcagcac agtttttagag aacaattgtt 360
 ataattaaat gataaggtag aatattttct catataaatt ctggctggcg tggaaatat 420
 cttattggta gaaacaacta catcctggtc atcatcctgc ctftctctt atggttacia 480
 tgatatcac tgtttgagat gaggataaaa tactctgagt ccaaacccggg cccctctgct 540
 aaccatgttc atgccttctt ctttttcccta cag 573

2/39

FIG.3A

Eco RV-SpeI Fragment of Semliki Forest virus replicon

atcggcgagtg	cgccctccag	gagaatgatg	tctacgcaca	aataccactg	cgtatgcctt	60
atgcgcagcg	cagaagaccc	cgaaaggctc	gatagctacg	caaaagaact	ggcagcgcc	120
tccgggaagg	tgctggatag	agagatcgca	ggaataatca	ccgacctgca	gacctcatg	180
gtacgcccag	acgctgaatc	tcttaccttt	tgccctgata	cagacgtcac	gtgtcgtacg	240
gcagccgaag	tggccgtata	ccaggacgtg	tatgctgtac	atgcaccaac	atcgctgtac	300
catcaggcga	tgaagggtgt	cagaacggcg	tattggattg	ggttgacac	caccccgttt	360
atgttttgacg	cgctagcagg	cgcgtatcca	acctaagcca	caaacctggc	cgacgagcag	420
gtgttacagg	ccaggaaact	aggactgtgt	gcagcatcct	tgactgaggg	aagactcggc	480
aaactgtcca	ttctccgcaa	gaagcaattg	aaaccttgcg	acacagtcac	gttctcggtc	540
ggatctacat	tgtacactga	gagcagaaga	ctactgagga	gctggcactt	acctcccgta	600
ttccacctga	aaggtaaaca	atccittacc	tgtaggtgcg	ataccatcgt	atcatgtgaa	660
gggtacgtag	ttaaagaaat	cactatgtgc	cccggcctgt	acggtaaaa	ggtagggtac	720
gccgtgacgt	atcacgcgga	gggatctcta	gtgtgcaga	ccacagacac	tgtcaaaagg	780
gaaagagtct	catccctgt	atgcacctac	gtcccctcaa	ccatctgtga	tcaaatgact	840
ggcatactag	cgacgcagct	cacacgcgag	gcgcacacga	agttgttagt	gggattgaat	900
cgagggatag	ttgtgaacgg	aagaacacag	cgaaacacta	acacgatgaa	gaactatctg	960
cttcgcgattg	tgccgcgtgc	atttagcaag	tgggcgaggg	aatacaaggc	agacottgat	1020
gatgaaaaac	ctctgggtgt	ccgagagagg	tcacttactt	gtgcgtgctt	gtgggcattt	1080
aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccgacacat	agtgaaggtg	1140
ccctcagagt	ttaactcgtt	cgtcatcccg	agccataggt	ctacaggcct	cgcgaatcca	1200
gtcagatcac	cgattaagat	gcttttggcc	aagaagacca	agcgagagtt	aatacctgtt	1260
ctcagacgcgt	cgctcagccag	ggatgctgaa	caagaggaga	aggagaggtt	ggagccgag	1320
ctgactagag	aagccttaac	acccctcgtc	cccatcgcgc	cgccggagac	gggagtcgtc	1380
gacgtcgacg	ttgaagaact	agagtatcac	gcaggtgcag	gggtcgtlga	aacactcgc	1440
agcgcgttga	aagtcaccgc	acagccgaac	gacgtactac	taggaaatta	cgtagttctg	1500

FIG.3B

ccccgcga	ccgtgctcaa	gagctccaag	ttggcccccg	tgcacctct	agcagagcag	1560
gtgaaataa	taacacataa	cggagggcc	ggcggttacc	aggtgcacgg	atatgacggc	1620
agggctctac	taccatgttg	atcgccatt	ccggtccctg	agtttcaagc	tttgatcgag	1680
agcgcacta	tggtgtacaa	cgaaaggag	ttcgtcaaca	ggaaactata	ccatatgtgc	1740
gttcacggac	cgctcgctgaa	cacgcgcag	gaaaactacg	agaaagtcag	agctgaaaga	1800
actgacccg	agtcagtgtt	cgagctagat	aaaaactgct	gcgtcaagag	agaggaagcg	1860
tcgggtttgg	tgttggtggg	agagctaac	aaccccccgt	tccatgaatt	cgctacgaa	1920
ggcggtgaag	tcaggccgtg	ggcaccatat	agaactacag	tagtaggagt	ctttggggtt	1980
ccgggatcag	gcaagtctgc	tattattaag	agcctctgta	ccaaacacga	tctggtcacc	2040
agcggcaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	ccgcggggaag	2100
gggacaagta	gggaaaacag	tgactccatc	ctgtctaacg	ggtgtcgtcg	tgccgtggac	2160
atccatatag	tggacgaggg	tttcgcttgc	cattccggtg	ctctgctggc	cctaattgct	2220
cttggttaaac	ctcgagagcaa	agtgggttta	tgcggagacc	ccaagcaatg	cggtattcttc	2280
aatatgatgc	agcttaaggt	gaacttcaac	cacaacatct	gcactgaagt	atgtcataaa	2340
agtatatcca	gacgtttgcac	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	2400
ggcaagatgc	gcacgaccaa	cccgctgcaac	aaacccataa	tcatagacac	cacaggacag	2460
accaagccca	agccaggaga	catcgtgtta	acatgcttcc	gaggtctggg	aaagcagctg	2520
cagltggact	accgtggaca	cgaaagtatg	acagcagcag	catctcaggg	cctcaccgcg	2580
aaaggggtat	acgccttaag	gcagaaggtg	aatgaaaatc	ccttgtatgc	ccctggtctg	2640
gagcacgtlga	atgtactgt	gacgcgcact	gaggataggg	tggtgtggaa	aacgttgccc	2700
ggcgatccct	ggattaaggt	cctatcaaac	atccacagg	gtaactttac	ggccacattg	2760
gaagatggc	aagaagaaca	cgacaaaata	atgaaggtga	tgaaggacc	ggctgcgctt	2820
gtggacgcgt	tccagaacaa	agcgaacgtg	tgttggcgga	aaagccttgg	gcctgtctgt	2880
gacactgccc	gaatcagatt	gacagcagag	gagtggaaga	ccataattac	agcatttaag	2940
gaggacagag	cttactctcc	agtggtggcc	ttgaatgaaa	tttgcacca	gtactatgga	3000
gttgacctgg	acagtggcct	gttttctgcc	ccgaagggtg	ccctgtatta	cgagaacaac	3060

4/39

000000-22235500

FIG.3C

cactgggata	acagacctgg	tgaaggatg	tatgattca	atgccgcaac	agctgccagg	3120
ctggaagcta	gacataacct	cctgaagggg	cagtgacata	cgggcaagca	ggcagttatc	3180
gcagaagaag	aatccaacc	ctcttctgtg	ctggacaatg	taattcctat	caacgcagg	3240
ctgcccacg	cccttggtggc	tgagtacaag	acggttaag	gcagtagggt	tgagtggctg	3300
gtcaataaag	taagagggt	ccagtcctg	ctggtgagt	agtacaacct	ggctttgcct	3360
cgacgcagg	tcaattggt	gtcacgctg	aatgtcacag	gcgccgatag	gtgtacgac	3420
ctaagtttag	gactgccggc	tgacgcggc	aggttcgact	tggtctttgt	gaacttcac	3480
acggaattca	gaatcacca	ctacagcag	tgtgtcgacc	acgccatgaa	gtgcagatg	3540
cttgggggag	atgggtacg	actgctaana	ccggcgcca	tcttgatgag	agcttacgga	3600
tacgccgata	aatcagcga	agcgttggt	tcctccttaa	gcagaaagt	ctcgtctgca	3660
agagtgttc	gccggattg	tgtcacagc	aatacagaag	tgttcttgct	gttctccaac	3720
tttgacaacg	gaaagagacc	ctctacgta	caccagatga	ataccaagct	gagtgccctg	3780
tatgccggag	aagccatgca	cacggccggg	tgtgcacct	ctacagagt	taagagagca	3840
gacatagcca	cgtgcacaga	agcggctgtg	gttaacgcag	ctaacgccc	tggaactgta	3900
ggggatggcg	tatgcagggc	cgtggcgaag	aaatggcctg	cagcctttaa	gggagcagca	3960
acacacgtgg	gcacaattaa	aacagtcatg	tgcggctcgt	accccgctcat	ccacgtgta	4020
gcgcctaatt	tctctgccac	gactgaagcg	gaaggggacc	gcgaattggc	cgtgtctac	4080
cgggcagttg	ccgcgcgaagt	aaacagactg	tcactgagca	gcgtagccat	cccgctgctg	4140
tccacaggag	tgttccagcg	cggaaagatg	aggctgcagc	aatccctcaa	ccatctattc	4200
acagcaatgg	acgccacgga	cgctgacgtg	accatctact	gcagagacaa	agattgggag	4260
agaaaaatcc	aggaagccat	tgacatgagg	cggctgtggtg	agttgctcaa	tgagtgaagt	4320
gagctgacca	cagacttggt	gagagtgcac	ccggacagca	gccttggtggg	tcgtaagggc	4380
tacagtacca	ctgacgggtc	gctgtactcg	tactttgaag	gtacgaat	caaccaggct	4440
gctatgata	tggcagagatg	actgacgttg	tggccacagac	tgaagagggc	aaacgaacag	4500
atatgcttat	acgcgctggg	cgaacaatg	gacaacatca	gatccaaatg	tccggtgaac	4560
gattccgatt	catcaaaccc	tcccaggaca	gtgcctcgcc	tgtgcgcgta	cgcaatgaca	4620

5/39

FIG.3D

WO 99/25859

PCT/CA98/01065

6/39

gcagaacgga	tcgcccgcct	taggtcacac	caagttaaaa	gcatggtggt	ttgtcatctt	4680
tttccctcc	cgaaatacca	tgtagatggg	gtgcagaagg	taaaagtcca	gaaggttctc	4740
ctgttcgacc	cgacggtaac	ttaagtgttt	agtcgcgga	agtatccgc	atctacgacg	4800
gaccactcag	atcgtgtcgt	acgagggttt	gacttgact	ggaccacga	ctcgtcttcc	4860
actgccagcg	ataccatgtc	gtctaccagt	ttagctcgt	gtgacatcca	ctcgatctac	4920
gagccaatgg	ctcccatagt	agtgacggct	gcgtacacc	gtgaacccg	aggcatccgc	4980
gacctggcgg	cgatgtgca	ccttgaaccc	gcagaccatg	tggacctcca	gaacccgatt	5040
cctccaccgc	gcccgaagag	agctgcatac	cttgctctcc	gcgcggcgga	gcgaccgggtg	5100
cgggcgccga	gaaagccgac	gcctgcccc	aggactcgct	ttaggaacaa	gctgcctttg	5160
acgttcggcg	actttgacga	gcacgaggct	gatgcgttgg	cctccgggat	tactttcgga	5220
gacttcgacg	acgtctctcg	actaggccgc	gcgggtgcat	atattttctc	ctcggacact	5280
ggcagcggac	atttacaaca	aaaatccgtt	aggcagcaca	atctccagtg	cgcacaactg	5340
gatcgggtcc	aggaggagaa	aatgtaccgc	cctaaatggg	atactgagag	ggagaagctg	5400
ttgtctgtga	aatgtcagat	gcacctatcg	gaggctaata	agagtcgata	ccagtcctgc	5460
aaagtggaga	acatgaaaagc	cacggtggtg	gacaggctca	catcgggggc	cagattgtac	5520
acgggagcgg	acgttaggccg	cataccaaca	tacgcggttc	ggtacccccg	cccggtgtac	5580
tcccctaccg	tgatcgaaaag	atttcaagc	cccgatgtag	caatcgcagc	gtgcacgaa	5640
tacctatcca	gaaattaccc	aacagtggcg	tcgtaccaga	taacagatga	atacagcgca	5700
tacttggaca	tggttgacgg	gtcggatagt	tgcttggaca	gagcgacatt	ctgcccgctc	5760
aagctccgggt	gctaccggaa	acatactcg	taccaccagc	cgactgtacg	cagtgccgtc	5820
ccgtcacccct	tcagaacac	actacagaac	gtgctagcgg	ccgcaccaca	gagaactgc	5880
aagctcacgc	aaatgggaga	actaccacc	atggactcgg	cagtggttcaa	cgtggagtcg	5940
ttcaagcgtc	atgccttgctc	cggagaatat	tgggagaagaat	atgctaaaca	acctatccgg	6000
ataaccactg	agaacatcac	tacctatgtg	accaaaatga	aaggccccga	agctgctgcc	6060
ttgttcgcta	agaccacaa	cttggttccg	ctgcaggagg	ttcccatgga	cagattcacg	6120
gtcgacatga	aacgagatgt	caaagtcact	ccaggggacga	aacacacaga	ggaaagaccc	6180

FIG.3E

aaagtccagg	taattcaagc	agcggagcca	ttggcgaccg	cttacctgtg	cggcatccac	6240
agggaaattag	taaggagact	aaatgctgtg	ttacgcccta	acgtgcacac	attgtttgat	6300
atgtcggccg	agacttttga	cgcgatcatc	gcctctact	tccaccagg	agaccgggt	6360
ctagagacgg	acattgcac	attcgacaaa	agccaggacc	actccttggc	tcttacaggt	6420
ttaatgatcc	tcgaagatct	aggggtggat	cagtacctgc	tggactttgat	cgaggcagcc	6480
tttggggaaa	tatccagatc	gaacttacca	actggcacgc	gcttcaagt	cggagctatg	6540
atgaaatcgg	gcatttttct	gactttgttt	attaacactg	ttttgaacat	caccatagca	6600
agcagggtac	tggagcagag	actcactgac	tccgcctgtg	cggccttcac	cggcgacgac	6660
aacatcgttc	acggagtgat	ctccgacaag	ctgatggcgg	agaggtgcgc	gtcgttgggtc	6720
aacatggagg	tgaagatcat	tgcgctgtc	atggcgcaaa	aaccccata	tttttgggg	6780
ggattcatag	tttttgacag	cgtcacacag	accgcttgcc	gtgtttcaga	cccacttaag	6840
cgcctgttca	agttgggtaa	gcgctaaca	ctcgaagaca	agcaggacga	agacaggcga	6900
cgagcactga	gtgacgaggt	tagcaagtgg	ttccggagac	gcttgggggc	cgaactggag	6960
gtggcactaa	catctaggta	tgaggtagag	ggctgcaaaa	gtatcctcat	agccatggcc	7020
accttggcga	gggacattaa	ggcgtttaag	aaattgagag	gacctgttat	acacctctac	7080
ggcgttccta	gatttggtcg	ttaatacaca	ttacatcctt	tggatcatag	cgcactatta	7140
taggattccag	atcccgggta	attaattgaa	ttgcctgtg	acgcaaacgt	tttacggccg	7200
ccggtggcgc	cgcgcgcccg	cggcccgctc	tgccgccttg	caggccactc	cggttggctcc	7260
cgtcgtcccc	gacttccagg	cccgacagat	cgcgaactc	atcagcgccg	ttaatgcgct	7320
gacaatgaga	gacaaacgcaa	ttgtcctcgc	taggcctccc	aaaccaaga	agaagaagac	7380
accacaaaca	aagccgaaaa	cgcagcccaa	gaagatcaac	ggaaaaacgc	agcagcaaaa	7440
gaagaaagac	aagcaagccg	acaagaagaa	gaagaaaccc	ggaaaaagag	aaagaatgtg	7500
catgaagatt	gaaaatgact	gtatcttctg	atcgggctag	ccacagtaac	gtagtgttc	7560
cagacatgtc	gggcacgcga	ctatcatggg	tgcagaaaaa	ctcgggtgtt	ctgggggctc	7620
tccgaatcgg	cgtatctctg	gtcgtggttg	gggtcacttg	catctgggctc	cgcagataag	7680
ttagggttagg	caatggcatt	gatatagcaa	gaaaatttga	aacagaaaaa	gttagggtaa	7740

7/39

FIG.3F

gcaatggcat	ataaccataa	ctgtataact	tgtaacaaag	cgcaacaaga	cctgcgcaat	7800
tggcccccgtg	gtccgcctca	cggaaactcg	gggcaactca	tattgacaca	ttaattggca	7860
ataattggaa	gcttacataa	gcttaattcg	acgaataatt	ggatttttat	tttattttgc	7920
aattggtttt	taatatattcc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	7980
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				8010

FIG. 4A

Nucleotide sequence of pSFVlink

gatggcggat gtgtgacata cacgacgcca aagattttt ttccagctcc tgccacctcc 60
 gctacgcgag agattaacca ccacgatgg ccgcaaaagt gcatgttgat attgaggctg 120
 acagcccatt cataagtct ttgcagaagg catttcgcg gtctgaggtg ggtcattgct 180
 aggtcacacc aaatgacct gcaatggcca gagcattttc gcacctggct accaaattga 240
 tcgagcagga gactgacaaa gacacactca tcttgatat cggcagtgcg ccttcaggga 300
 gaatgatgtc tacgcacaaa taccactgcg tatgcctat gcgcagcgca gaagaccccc 360
 aaaggctcga tagctacgca aagaaactgg cagcggcctc cgggaagggtg tggtagag 420
 agatcgcagg aaaaatcacc gacctgcaga ccgtcatggc taagccagac gctgaatctc 480
 ctaccttttg cctgcataca gacgtcacgt gtcgtacggc agccgaagtg gccgtatacc 540
 aggacgtgta tgcgtgtacat gcaccaacat cgcgtgtacca tcaaggcgatg aaaggtgtca 600
 gaacggcgta ttggattggg tttagacca ccccgtttat gtttgacgcg ctaggcaggcg 660
 cgtatccaac ctacgccaca aactggcgcg acgagcaggt gttacaggcc aggaacatag 720
 gactgtgtgc agcatccttg actgagggaa gactcggcaa actgtccatt ctccgcaaga 780
 agcaatgaa accttcggac acagtcatgt tctcgttagg atctacattg tacaatgaga 840
 gtagaagct actgaggagc tggcacttac cctccgtatt ccacctgaaa ggtaacaat 900
 ccttacctg tagtgcgat accatcgtat catgtgaag gtacgtagtt aagaaatca 960
 ctatgtgccc cggcctgtac ggtaaaaagg tagggtaacg cgtgacgtat cacgggagg 1020
 gattcctagt gtgcaagacc acagacactg tcaaggaga aagagtctca ttcctctgat 1080
 gcaactacgt cccctcaacc atctgtatc aaatgactgg catactagcg accgactga 1140
 cacggaggga cgcacagaag ttgttagtgg gattgaatca gaggatagtt gtgaacggaa 1200
 gaacacagcg aaacactaac acgatgaaga actatctgct tccgatttgt gccgtcgcat 1260
 ttgacaagtg ggcgagggaa tacaaggcag accttgatga tgaaaaacct ctgggtgtcc 1320
 gagagaggtc acttacttgc tgctgcttgt gggcatttaa aacgaggaag atgcacacca 1380
 tgtacaagaa accagacacc cagacaatat tgaagggtgcc ttacagagttt aactcgttcg 1440

9/39

FIG.4B

WO 99/25859

PCT/CA98/01065

tcattcccgag	cctatgggtct	acaggcctctg	caatcccagt	cagatcacgc	attaagatgc	1500
ttttggccaa	gaagaccaag	cgaagattaa	tacctgttct	cgacgcgtcg	tcagccaggg	1560
atgtgtaaca	agaggagaag	gagaggttgg	aggccagact	gactagagaa	gccttaccac	1620
ccctctgccc	catctgcgcc	gcgagacggg	gagtcgtcga	cgtcgacgtt	gaagaactag	1680
agtatcacgc	agggtgcagg	gtcgtggaaa	cacctcgag	cgcggtgaaa	gtcacccgac	1740
agccgaacga	cgtactacta	ggaattatcg	tagttctgtc	cccgcagacc	gtgctcaaga	1800
gctccaagtt	ggccccctg	cacctctag	cagagcaggt	gaaaataata	acacataacg	1860
ggaggggccgg	cggttaccag	gtcgacggat	atgacggcag	ggtcctacta	ccatgtggat	1920
cgggccattcc	ggtccctgag	tttcaagctt	tgagcgagag	cgccactatg	gtgtacaacg	1980
aaaggggagt	cgtcaacagg	aaactatacc	atatggcgt	tcacggaccg	tcgctgaaca	2040
ccgacgagga	gaactacgag	aaagtcagag	ctgaaagaac	tgacgccgag	tacgtgttcg	2100
acgtagataa	aaaatgctgc	gtcaagagag	aggaagcgtc	gggttttggtg	ttggtgggag	2160
agctaaccaa	cccccgctc	catgaattcg	cctacgaagg	ggtgaagatc	aggcgcgtcg	2220
caccatataa	gactacagta	ttaggagttct	ttggggttcc	gggatcaggc	aagtctgcta	2280
ttattaagag	cctcgtgacc	aaacagatc	tggtcacccg	cgccaagaag	gagaactgcc	2340
aggaaaatagt	taacgacgtg	aagaagcacc	gcgggaagg	gacaagtagg	gaaaacagtg	2400
actccatcct	gctaaacggg	tgtcgtcgtg	ccgtggacat	ccatatatgtg	gacgaggctt	2460
tgcgttgcca	ttccggtact	ctgctggccc	taattgctct	tgttaaacct	cggagcaaa	2520
tggtgttatg	cggagacccc	aagcaatgcg	gattcttcaa	tatgatgcag	cttaagttga	2580
acttcaacca	caacatctgc	actgaagtat	gtcataaaa	tatatccaga	cgttgcaacg	2640
gtccagtcac	ggccatcgtg	tctacgttgc	actcagagg	caagatgcgc	acgaccaacc	2700
cgtgcaacaa	accataatc	atagacacca	caggacagac	caagcccaag	ccaggagaca	2760
tcgtgttaac	atgcttcoga	ggctggggcaa	agcagctgca	gttggactac	cgtggacacg	2820
aagtgctgac	agcagcagca	tctcagggcc	tcaccgccaa	aggggtatatac	gccgtaaggg	2880
agaaggtgaa	tgaataatcc	ttgtatgcc	ctgcgtcggg	gcacgtgaat	gtactgctga	2940
cgcgcactga	ggataggctg	gtgtggaaaa	cgctggccgg	cgatccctgg	attaaggtcc	3000

10/39

FIG.4C

tatcaaacat	tccacagggt	aactttacgg	ccacattgga	agaatggcaa	gaagaacacg	3060
acaaaataat	gaaggtgatt	gaaggaccgg	ctgcgcctgt	ggacgcgttc	cagaacaaa	3120
cgaacgtgtg	tgggcgaaa	agcctggtgc	ctgtccttga	cactgcggga	atcagattga	3180
cagcagagga	gtggagcacc	ataattacag	catttaagga	ggacagagct	tactctccag	3240
tggtggcctt	gaatgaaatt	tgacccaagt	actatggagt	tgacctggac	agtggcctgt	3300
tttctgcccc	gaaggtgtcc	ctgtattacg	agaacaacca	ctgggataac	agacctggtg	3360
gaaggatgta	tggtatcaat	ggcgaacacg	ctgccaggct	ggaagctaga	cataccttcc	3420
tgaaggggga	gtggcatatc	ggcaagcagg	cagttatcgc	agaaagaaaa	atccaaccgc	3480
tttctgtgct	ggacaatgta	attcctatca	accgcaggct	gccgcacgcc	ctggtggctg	3540
agttacaagac	ggttaaaaggc	agtagggttg	agtggctggt	caataaagta	agaggttacc	3600
acgtcctgct	ggtgagtgag	tacaacctgg	ctttgcctcg	acgcagggtc	acttggttgt	3660
caccgctgaa	tgtcacaggc	gccgataggc	gctacgacct	agatttagga	ctgcgggctg	3720
acgcgggcag	gttcgacttg	gtcttttga	acattcacac	tgggggagat	gcgtacgcac	3780
accagcagtg	tgtcgaccac	gccatgaagc	cttacggata	gcgcgataaa	atcagcgaag	3840
tgctaaaacc	cggcggcatc	ttgatgagag	cgtctgcaag	agtgttgccg	cgggattgtg	3900
cogttgtttc	ctccttaagc	agaaaagttct	ttctccaaact	tgacaacgga	aagagacctt	3960
tcaccagcaa	tacagaagtg	ttcttgcctg	gtgccgtgta	tgccggagaa	gccatgcaca	4020
ctacgctaca	ccagatgaat	accaaagtga	agagagcaga	catagccacg	tgcacagaag	4080
cggcgggggtg	tgccaccatc	tacagagtta	gaactgtagg	ggatgtgcga	tgcaaggcgc	4140
cggctgttgg	taacgcagct	acagcccggtg	gaactgtagg	gagcagcaac	accaattaaaa	4200
tgccgaagaa	atggccgtca	gcccttaagg	gagcagcaac	accagtgggc	accaattaaaa	4260
cagtcattgtg	cggctcgtac	cccgctcatcc	acgctgtagc	gcctaatttc	tctgccacga	4320
ctgaagcggga	aggggaccgc	gaattggccg	ctgtctaccg	ggcagttggcc	gccgaagtaa	4380
acagactgtc	actgagcagc	gtagccatcc	cgtgtgtgtc	cacaggagtg	ttcacggcgc	4440
gaagagatag	gctgcagcaa	tccttcaacc	atctattcac	agcaattggac	gccacggcgc	4500
ctgacgtgac	catctactgc	agagacaaaa	gttggggagaa	gaaaatccag	gaagccattg	4560

11/39

FIG.4D

acatgaggac ggctgtggag ttgtcfaatg atgacgtgga gctgaccaca gacttggtga 4520
 gagtgcaccc ggacagcagc ctggtgggtc gtaagggtta cagtaccact gacgggtcgc 4580
 tgtactcgta ctttgaaggt acgaaattca accaggctgc tattgatatg gcagagatgc 4740
 tgacgtttgt gccagactg caagaggcaa caagacagat acgctatgc atgcctatgc 4800
 aaacaatgga caacatcaga tccaatgtc cggtagacga gtaggttca tcaacacct 4860
 ccaggacagt gactgcctg tgcgctatg caatgacagc agaagattc gcccgctta 4920
 ggtcacacca agttaaagc atggtggtt cgtcatctt tccctcccg aaataccatg 4980
 tagatggggt gcagaaagta aggttctct gttgacccg acggtacctt 5040
 cagtggttag tccgcggaag tatgcgcgat ctacgacgga ccactcagat cggtcgttac 5100
 gagggtttga cttggactgg accacgact cgtcttccac tgccagcgat accatgtcgc 5160
 taccagttt gcagtcgtg gacatcgact cgatctcaga gccaatgggt cccatagtag 5220
 tgacggctga cgtacacct gaaccgcag gcatcgcgga cctggcgca gatgtgcacc 5280
 ctgaacccgc agaccatgtg gacctcgaga acccgattcc tccaccgcgc cgaagagag 5340
 ctgcataacct tgcctccgc gcggcgagc gaccggtgcc ggcgccgaga aagccgacgc 5400
 ctgcggccaag gactcggtt tccgggatta ctttcggaga cttcgacgac gtccctgcgc 5460
 agagccgcgc ggggtgcata attttctct cggacactgg cacaactgga tgcggtccag 5520
 aatccgttag gcagcacaat actgcataag agtcgatacc gattgtacac gggagcgagc 5580
 tgtaccgcgc aaaaatggat actgagaggg agactcgcaa agtggagaac atgaaagcca 5640
 acccatcgga ggctaataag ctcgggggcca gttgttact ccgttactc cctaccgtg 5700
 cgttggttga cgcggttcgg taccctccgc gcaacgaata cctatccaga aattaccaca 5760
 taccacaata cgcggttcgg taccctccgc gcaacgaata cctatccaga aattaccaca 5820
 tctcaagccc cgtgttagca atcgcagcgt acagatgaat acgacgcata cttggacatg 5880
 cagtggcgtc gtaccagata cttggacatg acgacgcata cttggacatg gttacgggtt 5940
 cggatagttg cttggacaga gcgacattct gcccgcgcaa gtcgggtgc taccgaaac 6000
 atcatgcgta ccaccagcgc actgtacgca gtgccgtccc gtcacccctt cagaacacac 6120

12/39

FIG.4E

WO 99/25859

09/554333

PCT/CA98/01065

tacagaacgt	gctagcgcc	gccaccaaga	gaaactgcaa	cgtcacgcaa	atgcgagaac	6180
taccaccat	ggactcgga	gtgtcaacg	tggagtgtt	caagcgat	gcctgctccg	6240
gagaatatg	ggaagaat	gtaaacaa	ctatccgat	aaccactgag	aacatcata	6300
ccatgtgac	caaatgaa	ggccgaaag	ctgctgcct	gttcgctaag	accacaact	6360
tggttccgt	cgaggaggt	ccatggaca	gattcacgt	cgacatgaa	cgagatgtca	6420
aagtcactc	aggagcga	cacacagag	aaagaccac	agtcaggta	attcaagcac	6480
cggagccatt	ggcgaccgt	tactgtgcg	gcattccac	ggaattagta	aggagactaa	6540
atgctgtgt	acgcctaac	tgacacat	tgtttgat	gtcggccgaa	gactttgacg	6600
cgatcatcgc	ctctcactc	caccagag	accggttct	agagacggac	attgcatcat	6660
tcgacaaaag	ccaggacgac	tccttggct	ttacaggtt	aatgatcctc	gaagatctag	6720
gggtggatca	gtactgtcg	gacttgatg	aggcgcctt	tggggaata	tccagctgtc	6780
acctaccaac	tggcacgcg	ttcaagttcg	gagctatgat	gaaatcgggc	atgtttctga	6840
ctttgtttat	taacactgtt	ttgaacatca	ccatagcaag	cagggtactg	gagcagagac	6900
tcactgactc	cgctgtgcg	gccttcacg	gcgacgacaa	catcgttcac	ggagtgatct	6960
ccgacaagtc	gatggcgag	aggtgcggt	cgtgggtcaa	catggagggtg	aagatcatctg	7020
acgctgtcat	ggcgaaaaa	ccccatatt	tttgtgggg	attcatagtt	tttgacagcg	7080
tcacacagac	cgctgcgct	gtttcagacc	cacttaagcg	cctgttcaag	tgggttaagc	7140
cgctaacagc	tgaagacaag	caggacgaag	acaggcgacg	agcactgagt	gagaggtta	7200
gcaagtgggt	ccggacaggc	tggggggcg	aactggaggt	ggcactaaca	tctaggtatg	7260
aggftagaggg	ctgcaaaagt	atctctcatg	ccctcaccg	cttggcgag	gacatcaag	7320
cgtttaagaa	attctgattg	cgctgtatc	acctctacg	cggtccctaga	tgggtcggtt	7380
aatacacaga	attctgattg	gatcatagcg	cactattata	ggatccagat	cccggttaat	7440
taattgaatt	acatccctac	gcaaacgttt	tacggccgc	ggtggcgccc	ggcgccggcg	7500
ggccgttcctt	ggccgttgca	ggccactccg	gtggctcccg	tgcgtcccca	cttcagagcc	7560
cagcagatgc	agcaactcat	cagcgccgta	aatgcgtga	caatgagaca	gaacgcaatt	7620
gctcctgtcta	ggctcccaa	accaaagaag	aagaagacaa	ccaaacccaa	gccgaaaaacg	7680

13/39

FIG.4F

WO 99/25859

PCT/CA98/01065

cagcccaaga agatcaacgg aaaaacgcag cagcaaaaga agaaagacaa gcaagccgac 7740
 agaagaaga agaaacccgg aaaagagaa agaattgca tgaagattga aaatgactgt 7800
 atcttcgtat ggggtagcc acagtacgt agtgttcca gatagtgcg gcaccgcact 7860
 atcatgggtg cagaaaaatct cgggtggtct gggggccttc gcaatcgcg ctatcctggt 7920
 gctgggtgtg gtcacttgca ttgggtctcg cagataagtt aggttagga atggcattga 7980
 tatagcaaga aaattgaaaa cagaaaaagt taggttaagc atggcatat aaccataact 8040
 gtataacttg tacaacagc caaacagacc tgcgcaattg gcccgctggt ccgcctcacg 8100
 gaaactcggg gcaactcata ttgacacatt aattggcaat aattggaagc ttacataagc 8160
 ttaattcgac gaataattgg atttttat ttatttgcaa ttggttttta atatttccaa 8220
 aaaaaaaaa aaaaaaaa aaaaaaaa ccaacgcgcg cggagaggcg gtttgcgtat 8280
 aaaaaaaact agtctgcatt aatgaatcgg ctgcctcgt ctcgtgcgc tgggtcgttc 8340
 tgggcgctct tccgcttcct cgcctactga atcggttatc acagaatcag gggataaacg 8400
 agcgggtatca gctcaactcaa aggcggtaat aaagcccgag aaccgtaaaa aggcgcggtt 8460
 aggaagaac atgtgagcaa aggccagca tgacgagcat cacaataatc gacgtcaag 8520
 gctggcggtt ttccatagcg tccgcctccc aagataccag gcgtttcccc ctggaagctc 8580
 tcagagggtg cgaacccgca caggactata gcacctgcc gcttaccgga tacctgtccg 8640
 cctcgtgcgc tctcctgttc cgacctgcc ctcaatgct gcgctgtagg accccccgtt 8700
 ttccgggaagc gtggcgcttt ctcaatgct gcgctgtagg accccccgtt 8760
 cgttcgctcc aagctgggct gtgtgcaga agtccaacc ggtaagacac gacttatcgc 8820
 atccggtaac tatcgtcttg agtccaacc ggtaagacac gacttatcgc cactggcagc 8880
 agccactggt aacagatta gcagagcgag cactagaag gacagtattt ggtatctgcg 8940
 gtggtggcct aactacggt aactagaag gacagtattt ggtatctgcg ctctgctgaa 9000
 gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaacaaa ccaccgctgg 9060
 tagcgtgggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 9120
 agatcctttg atcttttcta cggggtctga cgctcagttg aacgaaaaact cacttaagg 9180
 gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 9240

FIG.4G

WO 99/25859

PCT/CA98/01065

09/554333

aagttttaaa	tcaatctaaa	gtatatatga	gtaaacttgg	tctgacagtt	accaatgctt	9300
aatcagtgag	gcacctatct	cagcgatctg	tctatttogg	tcatccatag	ttgcctgact	9360
ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	tctggcccc	gtgctgcaat	9420
gataccgcga	gaccacgct	caccggtcc	agattttaca	gcaataaacc	agccagccgg	9480
aaggggccgag	cgagaagtg	gtcctgcaac	ttttatccgc	tccatccagt	ctattaattg	9540
ttgcctgggaa	ctcagagtaa	gtagtctgcc	agtttaagt	ttgcgcaacg	ttgttgccat	9600
tgatcagagc	atcgttggtg	cacgtctcgt	gtttgggtatg	gcttcattca	gtcccggttc	9660
ccaacgatga	aggcgagtta	catgatcccc	catgttttgc	aaaaagcgg	ttagtcctt	9720
cggtctctccg	atcgtttgtca	gaagtaagtt	ggccgcaagt	ttatcactca	tggttatggc	9780
agcaactgcac	aattctctta	ctgtcatgcc	atccgttaaga	tgctttttctg	tgactggtga	9840
gtactcaacc	aagtcaattct	gagaatatgtg	tatgcggcga	ccgagttgct	cttgccccgcg	9900
gtcaatacgg	gataataccg	cgccacatag	cagaacttta	aaagtgtca	tcattggaaa	9960
acgtttcttg	ggcggaacac	tctcaaggat	cttaccgctg	ttgagatcca	gttcgatgta	10020
accactctgt	gcaccaact	gatcttcagc	atcttttact	ttcaccagcg	ttcttgggtg	10080
agcaaaaaca	ggaaggcaaa	atgccgcgaa	aaagggaata	agggcgacac	ggaaatgttg	10140
aatactcata	ctcttcttt	ttcaatatta	ttgaagcatt	tatcagggtt	attgtctcat	10200
gagcggtatc	atatttgaat	gtatttagaa	aaataaacaa	atagggttc	cgcgacatt	10260
tccccgaaaa	gtgccacctg	acgtctaaga	aaccattatt	atcatgacat	taacctataa	10320
aatataggcgt	atcacgaggc	cccttctgtc	agcgtctgtc	ggtgatgacg	gtgaaaaacct	10380
ctgacacatg	cagctcccg	agacggtcac	agcttctgtc	taagcgggat	ccgggagcag	10440
acaaagccctg	cagggcgctg	cagcggtgtg	tggcggtgtg	cggggctggc	ttactatgct	10500
ggcatccagag	cagatgtgtac	tgagatgtca	ccatatgcac	gctctccctt	atgcgactcc	10560
tgcatttagga	agcagccacg	tactaggttg	aggccgttga	gcaccgccgc	cgcgaaggat	10620
ggtgcatgca	aggagatggc	gccccacagt	cccccgcca	cggggcctgc	caccataccc	10680
agcccgaaac	aagcgtctat	gagccccgaag	tggcgagccc	gatcttcccc	atcggtgatg	10740
tggcgatat	aggcgccagc	aaccgcacct	gtggcgccgg	tgatgccggc	caugatcgct	10800

15/39

FIG.4H

ccggcgtaga	ggatctggct	agcgatgacc	ctgctgattg	gttcgctgac	catttccggg	10860
gtgcggaacg	gcgttaccag	aaatcagaa	ggttcgtcca	accaaacga	ctctgacggc	10920
agtttacgag	agagatgata	gggtctgctt	cagtaagcca	gatgctacac	aattaggctt	10980
gtacatatgg	tcgttagaac	gcggctacaa	ttaatacata	accttatgta	tcatacacat	11040
acgatttagg	tgacactata					11060

17/39

Construction of pSFVlink




FIG.5

FIG.6A

Nucleotide Sequence of pMP76

attggctatt ggccattgca tacgttgtat ctatatcata atatgtacat ttatatggc 60
 tcatgtccaa tatgaccgcc atgttgacat tgattattga ctgattatta atagtaatca 120
 attacggggt cattagtcca tagcccatat atggagttcc cggttataa acttacgta 180
 aatggcccg ctcgtgacg ccaacgacc ccgcccatt gacgtcaata atgacgtatg 240
 ttcccatagt aacgccaata gggaactttc attgacgtta atgggtggag tatttacggt 300
 aaactgccca cttggcagta catcaagtgt atccatagcc aagtcggcc cctattgacg 360
 tcaatgacgg taaatggccc gcttggcatt atgcccagta catgacctta cgggactttc 420
 ctacttggca gtacatctac gtattagtca tagcgggtttg actcaagggg catgtgtgat cggttttggc 480
 agtacaccaa tgggcgtgga ttttggcacc aaaaacacg ggactttcca aaatgtcgtg 540
 ttgacgtcaa tgggagtttg caaatggcgc atgtgtgaca tacacgacgc caaagatttt 600
 ataacccgc cccgttgacg cgaatggcgc agatgtgaca agagattaac caccacgat gcccgccaaa 660
 gcagagctcg tttagtgaac cctgcccact ccgtacgcg ttcattcaagt ctttgcaaaa 720
 tgttccagct atattgaggc tgacagccca ccaaatgacc atgcaaatgc cagagcattt 780
 gtgcattgtg tggagtcatt gcaggtcaca gagactgaca aataccactg cgtatgcctt 840
 tcggttcgagg ctaccaaatt gatcgagcag tctacgcaca gatagctac caaagaaact ggcagcggcc 900
 tcgcaccttg cgccttcacg gagaatgatg cgaaggctc ggaataatca ccgacctgca gacgtcatg 960
 atcgggcagt cgaagacccc tgcctggatag agagatcgca tgcctgcata cagacgtcac gtgtcgtacg 1020
 tccgggaagg acgctgaatc ccctacattt tatgctgtac atgcaccaac atcgtgttac 1080
 gctacgccag tggccgtata ccagacgtg cagaacggcg tattggattg acactgggc cgaacgtgacg 1140
 gcagccgaag catcaggcga cgtctagcagg cgcgtatcca acctacgcca ccaactgggc cgaacgtgacg 1200
 catcaggcga atgtttgacg

18/39

FIG.6B

gtgttacagg	ccaggaaacat	aggactgtgt	gcagcatcct	tgactgaggg	aagactcggc	1440
aaactgtcca	ttctcgcgaa	gaagcaattg	aaaccttgcg	acacagtcac	gtctcggta	1500
ggatctacat	tgtacactga	gagcagaag	ctactgagga	gctggcacct	acctccgta	1560
ttccacctga	aaggtaaaca	atcctttacc	tgtagtgcg	ataccatcgt	atcatgtgaa	1620
gggtacgtag	ttagaataat	cactatgtgc	ccggccctgt	acggtaaaa	ggtagggtag	1680
gcggtgacgt	ttacgcgga	gggattccta	gtgtgcaaga	ccacagacac	tgtcaaaagg	1740
gaaagagtct	cattccctgt	atgcacctac	gtccccctaa	ccatctgtga	tcaaatgact	1800
ggcatactag	cgacgcacgt	cacacgggag	gacgcacaga	agttgttagt	gggattgaat	1860
cagaggatag	ttgtgaacgg	aagaacacag	cgaacaccta	acacgatgaa	gaactatctg	1920
cttccgattg	tggccgtcgc	atttagcaag	tgggcgaggg	aatacaaggc	agaccttgat	1980
gatgaaaaac	ctctgggtgt	ccgagagagg	tcacttactt	gctgctgctt	gtgggcattt	2040
aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccagacaa	agtgaaggtg	2100
aaattcagagt	ttaactcgtt	cgtcatcccg	agcctatggt	ctacaggcct	cgcaatccca	2160
gtcagatcac	gcattaaagt	gcttttggcc	aagaagacca	agcgagagtt	aatacctgtt	2220
ctcgacgcgt	cgtcagccag	ggatgctgaa	caagaggaga	aggagaggtt	ggaggccgag	2280
ctgactagag	aagccttacc	acccctcgtc	cccatcgcgc	cggcgagagac	gggagtcgtc	2340
gacgtcgacg	ttgaagaact	agagtatac	gcaggtgcac	gggtcgtgga	aacacctcgc	2400
agcgcggtga	aaagtcacgc	acagccgaac	gacgtactac	taggaaatta	cgtagttctg	2460
tcccgcgaga	ccgtgctcaa	gagctccaa	ttggcccccgc	tgcacctct	agcagagcag	2520
gtgaaaaata	taacacataa	cgggagggcc	ggcggttacc	aggtcgacgg	atatgacggc	2580
agggctctac	taccatgtgg	atcgccatt	ccggtccctg	agttccaagc	tttgagcggag	2640
agcgcacta	tggtgtacaa	cgaaaggagg	ttcgtcaaca	ggaaactata	ccatattgcc	2700
gtttcaggac	cgtcgcgtgaa	caccgacgag	gagaactacy	agaaagtcag	agctgaaaga	2760
actgacgcgc	agtcactgtt	cgacgtagat	aaaaaatgct	aggtcaagag	aggtgaagcg	2820
tcgggtttcg	tggttggtggg	agagctaacc	aacccccgt	tccatgaatt	cgcctacgaa	2880
ggcgtgaaga	tcaggccgtc	ggcaccatat	aagactacag	tagtaggagt	ctttgggggt	2940

FIG.6C

WO 99/25859

09/554333

PCT/CA98/01065

ccgggatcag	gcaagtctgc	tattattaag	agcctcgtga	ccaaacacga	tctggtccac	3000
agcggcaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	ccgcgggaag	3060
gggacaagta	gggaaaacag	tgactccatc	ctgctaaacg	ggtgtcgtcg	tgccgtggac	3120
atcctatatg	tgagcaggcg	tttcgcttgc	cattccggtta	ctctgctagc	ccctaattgct	3180
cttgttaaac	ctcggagcaa	agtgtgtgta	tgcggagacg	ccaagcaatg	cggattcttc	3240
aatatgatgc	aggttaaggt	gaacttcaac	cacaacatct	gcactgaagt	atgtcataaa	3300
agtatatcca	gacgttgac	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	3360
ggcaagatgc	gcacgaccaa	ccgttgcaac	aaaccataa	tcatagacac	cacaggacag	3420
accaagccca	agccaggaga	catcgtgtta	acatgcttcc	gaggtctggc	aaagcagctg	3480
cagttggact	accgtggaca	cgaagtcacg	acagcagcag	catctcaggg	cctcacccgc	3540
aaaaggggtat	acgcgctaag	gcagaaggtg	aatgaaaatc	ccttgtatgc	ccctgcgtcg	3600
gagcacgtga	atgtactgct	gacgcgcat	gaggataggc	tggtgtggaa	aacgttgccc	3660
ggcgatccct	ggattaaggt	gagtttgggg	acccttgatt	gtctcttctt	tttcgctatt	3720
gttaaaattca	tgttatatgg	agggggcaaa	gttttcaggg	tggtgttttag	aatgggaaga	3780
tgtcccttgt	atcaccatgg	accctcatga	taattttgtt	tctttcacct	tctactctgt	3840
tgacaaccat	tgtctoctct	tattttcttt	tcattttctg	taactttttc	gttaaacctt	3900
agcttgcatt	tgtaacgaat	ttttaaatc	acttttgttt	atttgtcaga	ttgtaagtac	3960
tttctctaata	cacttttttt	tcaaggccaat	cagggtatat	tatatgttac	ttcagcacag	4020
tttttagagaa	caatttgttat	aattaaatga	taaggtagaa	tattttctgca	tataaattct	4080
ggctcggcgtg	gaaatatctt	tatttggtag	aacaactaca	tcctgtgcat	catectgctt	4140
ttctcttttat	ggttacaaatg	atatacacatg	tttgagatga	ggataaaaata	ctctgagtcc	4200
aaacccgggcc	ccctctgttaa	ccatgtttcat	gccttcttct	ttttcctaca	ggtcctatca	4260
aacatccac	agggttaact	tacggccaca	ttggaagaat	ggcaagaaga	acacgacaaa	4320
ataatgaagg	tgattgaagg	accggctcgg	cctgtggacg	cgttcacaga	caaaagcaac	4380
gtgtgttggg	cgaaaagcct	ggtgcctgtc	ctggacactg	coggaatcag	attgacagca	4440
gaggagtgga	gcaccataat	tacagcattt	aaggaggaca	gagcttactc	tccagtggcg	4500

20/39

FIG.6D

WO 99/25859

PCT/CA98/01065

gccttgaatg aaatttgcac caagtactat ggagttgacc tggacagtggt cctgtttttct 4560
 gccccgaagg tgtccctgta ttacgagaac aaccactggg ataacagacc tgggtggaagg 4620
 atgtatggat tcaatgcgc aacagctgcc aggtcggaag ctagacatac ctctctgaag 4680
 gggcagtgcc atacgggcaa gcaggcagtt atcgagaaa gaaaaatcca accgctttct 4740
 gtgctggaca atgtaattcc tatcaaccgc aggtcgccg cgcacctggg ggtgagttac 4800
 aagacggtta agggcagtag ggttgagttgg ctggtcaata aagtaagagg gtaccacgtc 4860
 ctgctgggtga tgaagtacaa cttggctttg cctcgacgca cctgacatg gttgtcaccg 4920
 ctgaattgtca caggcgccga taggtgtctac gacctaaagt taggactgcc ggtgacgcc 4980
 ggcaggttcc acttggttct ttgtaacatt cacacggaat tcagaatcca ccactaccag 5040
 cagtgtgtcg accacgccat gaagctgcag atgcttgggg gagatgcgt acgactgcta 5100
 aaacccggcg gcattctgat gagagcttac ggatacgccg ataaaaatcag cgaagccgtt 5160
 gtttccctct taagcagaaa gtctctgtct gctgttctcc aactttgaca tgcgcccga 5220
 agcaatacaga aagttgtctt gctgttctcc gctgagtgcc gcagacatag ccactgtcac 5280
 ctacaccaga tgaataccaa gctgagtgcc agttaagaga gcagacatag ccactgtcac 5340
 ggtgtgtcac catctctacag agttaaagaga cagtggaact gtaggggatg gogtatgcag 5400
 gtggttaacg cagctaacgc cgttgaact taaggagca gtaggccta ttctcttgc 5460
 aagaaatggc cgtcagcct cgtcagcct catccacgt taccggcag ctgtccacag 5520
 atgtgcggct cgtaccocgt ggcgcgtgtc ctgcccgccg agtaaacaga 5580
 gcggaagggg acccgcaatt ctcccccgtg caaccatcta ttccagcaa tggacgccac 5640
 ctgttactga gcagcgtagc catcccgtg caaaagttgg gagaagaaaa tccaggaaagc 5700
 gataggctgc agcaatccct actcgagaga caaatgatgac gtggagctga ccacagactt 5760
 gtgaccatct actcgagaga tggagttgct caatgcgttaag ggtctacagta ccaactgacg 5820
 agggacggctg tggagttgct cagcctggt gggtcgttaag gctgtatttg atatggcaga 5880
 caccgggaca gcagcctggt aaggtacgaa attcaaccag gctgtatttg atatggcaga 5940
 tcgtactttg aaggtacgaa attcaaccag gctgtatttg atatggcaga 6000
 ttgtggccca gactgcaaga ggcaaacgaa cagatatgcc tatacgcgct gggcgaaaca 6060

21/39

FIG. 6E

atggacaaca	tcagatccaa	atgtccgggtg	aacgatttcg	attcatcaac	acctcccagg	6120
acagtgccct	gcctgtgcg	ctacgcaatg	acagcagaac	ggatcgccc	ccttaggtca	6180
caccaagtta	aaagcatggt	ggtttgctca	tcttttcccc	tcccgaata	ccatgtagat	6240
ggggtgcaga	aggtaaagt	cgagaaggtt	ctctgttctg	accgcagggt	accttcagg	6300
gttagtcgc	ggaagtatgc	cgcactctacg	acggaccact	cagatcggtc	gttacgagg	6360
tttgacttgg	actggaccac	cgactcgtct	tccagtgcga	cgataccat	gtcgctacc	6420
agtttgagt	cggttgacat	cgactcgatc	tacagaccaa	tggctcccat	agtagtgac	6480
gctgacgat	acctggaacc	cgcaggcatc	gcggacctgg	cggcagatgt	gcacctgaa	6540
ccgcagacc	atgtggacct	cgagaacccc	attctccac	cgcgccgaa	gagagctgca	6600
taccttgct	ccgcgcggc	ggagcgaccg	gtgccggcg	cgagaaagcc	gacgcctgcc	6660
ccaaggactg	cgtttaggaa	caagctgcct	ttagcgttcg	gcgactttga	cgagcacgag	6720
gtcgaatcgt	tggctccgg	gattacttct	ggagacttcg	acgacgtcct	cgactaggc	6780
cgcgcgggtg	catatatctt	ctctcggac	actggcagcg	gacatttaca	acaaaatcc	6840
gttaggcagc	acaaatccca	gtgcgcacaa	ctggatgcgg	tccaggagga	gaaaatgtac	6900
ccgccaaaat	tggatactga	gagggagaag	ctgtgtctgc	tgaaaatgca	gatgcaccca	6960
tccggaggcta	ataagagtgc	ataccagtct	cgc aaagtgg	agaacatgaa	agccacgggtg	7020
gtggacaggc	tcacatcggg	ggccagattg	tacacgggag	cggacgtagg	cgcatacca	7080
acatacgcgg	tccgttacc	ccgcgccgtg	tactccctca	ccgtgatcga	aagattctca	7140
agccccgatg	tagcaatcgc	agcgtgcac	gaatacctat	ccagaaatta	cccaacagtg	7200
gggtcgtacc	agataacaga	tgaatacgac	gcatacttgg	acatggttga	cgggtcggat	7260
agtctgttgg	acagagcgac	attctgcgg	gcgaagctcc	ggtgtacc	gaacatcat	7320
gcgtaccacc	acgcgactgt	acgcagtgc	gtccccctac	cctttcagaa	cacactacag	7380
aacgtgtctag	cggccgcac	caagagaac	tgcacgtca	cgc aaatgcg	agaaactacc	7440
accatggact	cggcagtgtt	caacgtggag	tgtctcaagc	gctatgcctg	ctccggagaa	7500
tattgggaag	aatatgctaa	acaacctatc	cggataacca	ctgagaacat	cactacctat	7560
gtgaccaaat	tgaaggccc	gaagctgct	gccttgttgc	ctaagaccca	caacttgggt	7620

22/39

FIG.6F

WO 99/25859

09/554333

PCT/CA98/01065

ccgctgcagg	aggtttcccat	ggacagattc	acggtcgcaca	tgaacgcaga	tgtaaaagt	7680
actccaggga	cgaacacac	agaggaaga	cccaagtcc	aggtaatca	agcagcgag	7740
ccattggcga	ccgcttacct	gtcggcatc	cacagggaat	tagtaaggag	actaaatgct	7800
gtgttacgcc	ctaacgtgca	cacattgttt	gatatgtcgg	cgaagactt	tgacgcgatc	7860
atcgcccttc	acttccacc	aggagaccgg	ggtctagaga	cggacatgc	atcattcgct	7920
aaaagccagg	acgactcctt	ggctcttaca	ggttttaaga	tctctgaaga	tctatgggtg	7980
gatactgacc	gtcgtgactt	gatacggca	gcctttgggg	aaatatccag	ctgtcaccta	8040
ccaactggca	cgcgcttcaa	gttcggagct	atgatgaat	cgggcattgt	tctgaactttg	8100
tttattaaca	ctgttttgaa	catcaccata	gcaagcaggg	tactggagca	gagactcact	8160
gactccgcct	gtcgcgcctt	catcggcgac	gacaacatcg	ttcacggagt	gatctccgac	8220
aagctgatgg	cggagaggtg	cgcgtcgtgg	gtcaacatgg	aggtgaagat	cattgacgct	8280
gtcatggcgg	aaaaaccccc	atatttttgt	gggggattca	tagtttttga	cagcgtcaca	8340
cagaccgcct	gccgtgtttc	agaccactt	aagcgcctgt	tcaagtttgg	taagccgcta	8400
acagctgaag	acaagcagga	cgaagacagg	cgacgagcac	tgagtgcga	ggttagcaag	8460
tggttcggga	caggcttggtg	ggcgaactg	gaggtggcac	taacatctag	gtatgaggt	8520
gagggtcgca	aaagtatcct	catagccatg	gccaccttgg	cgagggacat	taaggcgttt	8580
aagaaattga	gaggacctgt	tatacacctc	tacggcggtc	ctagattggt	gcgttaatac	8640
acagaattct	gattggatca	tagccacta	ttataggatc	cagatcccg	gtaataatt	8700
gaattacatc	cctacgcaaa	cgtttacgg	cgcccggtgg	cgcccgcc	cggcggcccc	8760
tccctggccg	ttgcaggcca	ctccggtggc	tcccgctgc	cccgacttc	aggccacga	8820
gatgcagcaa	ctcatcagcg	ccgtaaatgc	gctgacaatg	agacagaacg	caattgctcc	8880
tgtaggcct	cccaaaccaa	agaagaagaa	gacaaccaaa	ccaaagccga	aaacgcagcc	8940
caagaagatc	aacggaaaaa	cgcagcagca	aaagaagaaa	gacaagcaag	ccgacaagaa	9000
gaagaagaaa	ccgggaaaaa	gagaaagaat	gtgcatgaag	attgaaaatg	actgtatctt	9060
cgtatcgccg	tagccacagt	aacgtagtgt	ttccagacat	gtcgggcacc	gcactatcat	9120
gggtgcagaa	aatctcgggt	ggctctggggg	ccttcgcaat	cggcgctatc	ctggtgctgg	9180

23/39

FIG.6G

WO 99/25859

09/554333

PCT/CA98/01065

24/39

ttgtggtcac	ttgcatggg	ctcgcagat	aagttaggg	aggcaatggc	attgatatag	9240
caagaaaatt	gaaacagaa	aaagttagg	taagcaatg	catataacca	taactgtata	9300
acttgaaca	aagcgcaaca	agactcgcc	aattggccc	gtggtccgcc	tcacggaaac	9360
tgggggcaac	tcataatgac	acattaattg	gcaataattg	gaagcttaca	taagttaaat	9420
tgcacgaata	attggatttt	tattttattt	tgcataattg	ttttaaat	tccaaaaaaa	9480
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	9540
aaacgggtcg	gcatggcatc	tccactctct	cgcggtccga	cctgggcatc	cgaaggagga	9600
cgcagctcca	tcaggatggc	taaggagat	cctgaactta	acgctcgagt	gccagccatc	9660
tgttgtttgc	ccctcccccg	tgccttctct	gacctggaa	ggtgccactc	ccactgtcct	9720
ttctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	9780
gggtgggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	9840
ggatgcgggtg	ggctctagga	tctcgacct	gcagggttaag	gatactgcc	ggaacaaaac	9900
catgatccctg	acgcgatgcc	agctagtct	taggtggagc	tccagctttt	gttcccttta	9960
gtgagggtta	atttcgagct	tggcgtaac	atggtcatag	ctgtttccctg	tgtgaaattg	10020
ttatccgctc	acaattccac	acaacatac	agccggaaagc	ataaagtga	aagcctgggg	10080
tgcctaataga	gtgagctaac	tcacattaat	tgcgtttgccc	tcactgccc	ctttccagtc	10140
gggaacacctg	tcgtgccagc	tgcattaatg	aatcggccaa	cgcgcgggga	gaggcggttt	10200
gcgtattggg	cgcctctccg	cttctcgcct	cactgactcg	ctgcgctcgg	tcgttcggct	10260
gcggcgagcg	gtatacagtc	actcaaggc	ggtaatacgg	ttatccacag	aatcagggga	10320
taacgcagga	aagaacatgt	gagcaaaaag	ccagcaaaag	gcagggaacc	gtaaaaaggc	10380
cgcgttgctg	cggtttttcc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	10440
ctcaagtccag	aggtggcgaa	accgcacagg	actataaaga	taccaggcgt	ttccccctgg	10500
aagctccctc	gtgcgctctc	ctgttccgac	cctgcccgtt	accggatacc	tgtccgctt	10560
tctcccttcg	ggaagcgtgg	cgctttctca	tagctcacgc	tgtaggatc	tcagttcggt	10620
gtaggtcggt	cgctccaagc	tgggctgtgt	gcacgaaccc	ccggttcagc	ccgacgcgtg	10680
cgcccttatcc	ggtaaactatc	gtctttgagtc	caaccgggta	agacacgact	tatcgccact	10740

FIG.6H

WO 99/25859

PCT/CA98/01065

25/39

ggcagcagcc	actggttaaca	ggattagcag	agcgaggtat	gtaggcgggtg	ctacagagtt	10800
cttgaagtgg	tggcctaact	acggtacac	tagaaggaca	gtatttggtg	tctgcgtct	10860
gctgaagcca	gttaccttcg	gaaaagagt	tggtagctct	tgatccggca	aaaaaccac	10920
cgtcgttagc	ggtggttttt	ttgttgcga	gcgcagatt	acgcgcagaa	aaaaaggatc	10980
tcaagaagat	ccttbtgatct	tttctacgg	gtatgcagct	cagtggaacg	aaaactcacg	11040
ttaagggatt	tttctcatga	gattatcaaa	aaggatcttc	acctagatcc	ttttaaatla	11100
aaaatgaagt	tttaaatcaa	tctaaagtat	atatgagtaa	acttgggtcg	acagttacca	11160
atgtcttaac	agtgaggcac	ctatctcagc	gatctgtcta	tttcgttcat	ccatagttgc	11220
ctgactccgg	ggggggggggg	cgtcagggtc	tgccctcgtg	agaaggtgtt	gctgactcat	11280
accaggcctg	aatcgcccca	tcattccagc	agaaagtgg	ggagcccacg	ttgatgagag	11340
ctttgttgtg	ggtggaccag	ttggtgattt	tgaacttttg	ctttgcccag	gaaaggctcg	11400
cgtttgtcgg	aagatggctg	atctgatcct	tcaactcagc	aaaagttcga	ttatttcaac	11460
aaagccgccc	tccggtcaag	tcagcgtaat	gctctgccag	tgttacaacc	aattaaaccaa	11520
tcttgattag	aaaaactcat	cgagcatcaa	atgaaactgc	aatttattca	tatcaggatt	11580
atcaatacca	tattttttgaa	aaagccgttt	ctgtaatgaa	ggagaaaaact	caccgaggca	11640
gttccatagg	atggcaagat	cctggtatcg	gtctgcgatt	ccgactcgtc	caacatcaat	11700
acaacctatt	aattttccct	cgtcaaaaaa	aaggtttatca	agtgagaaat	caccatgagt	11760
gacgactgaa	tccggtgaga	atggcaaaa	cttatgcatt	tctttccaga	cttgttcaac	11820
agggcagcca	ttagcgtcgt	catcaaaaat	actcgcataca	accaaacctg	tattcatctg	11880
tgattcgcgc	tgagcgagac	gaaatacgcg	atcgtctgta	aaaggacaaat	tacaaaacagg	11940
aatcgaatgc	aaccggcgca	ggaacactgc	cagcgcatca	acaatatattt	cacctgaatc	12000
aggatatctt	tctaatacct	ggaatgctgt	ttttcccgggg	atcgcagttgg	tgagtaacca	12060
tgcatacatca	ggagtacgga	taaaatgctt	gatggtcggg	agagtcataa	attccgtcag	12120
ccagttttagt	ctgaccatct	catctgtaac	atcatatggca	acgtacacct	tgccatgttt	12180
cagaaacac	tctggcgcat	cgggcttccc	atacaatcga	tagattgtctg	cacctgattg	12240
cccgacatta	tcgcgagccc	atttatcccc	atataaatca	gcattccatgt	tggaatttaa	12300

26/39

FIG. 6I

```

tcgcggcctc gagcaagacg ttccccgttg aatatggctc ataacacccc ttgtattact 12360
gtttatgtaa gcagacagtt ttattgttca tgatgatata tttttatatt gtgcaatgta 12420
acatcagaga ttttgagaca caacgttgct ttcccccccc cccccgagct tgat      12474

```

```

CMV promoter 1 - 682
SFV replicon (before intron) 684 - 3678
Rabbit (-globin intron II 3679 - 4251
SFV replicon (after intron) 4252 - 9543
Hepatitis Delta virus ribozyme (antigenomic) 9544 - 9628
Kanamycin Gene 12342 - 11503
BamHI site for insertion of heterologous inserts 8677

```

27/39
Subcloning of the SFV replicon




FIG.7

28/39

Construction of pMP76




FIG.8A




FIG.8B

30/39
Construction of pMP76




FIG.8C

31 / 39

Construction of pMP76 (cont'd)




FIG.8D

32/39

Construction of pMP53 & pMP54




FIG.9A

33/39

Construction of pMP55

cut pMP54 with Spe I and make blunt-ended with Mung Bean nuclease

cut with BgIII and dephosphorylate

ligate in phosphorylated linker-Hepatitis Delta virus ribozyme (antigenomic)

CGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCGACCTGGGCA . . .
 GCCCAGCCGTACCGTAGAGGTGGAGGAGCGCCAGGCTGGACCCGT . . .
 . . . TCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGA
 . . . AGGCTTCCTCCTGCGTGCAGGTGAGCCTACCGATTCCCTCTCTAG




FIG.9B

34/39
Construction of pMP52




FIG.10




FIG.11A

36/39

Construction of pMP70




FIG.11B

37/39
Construction of pMP71




FIG.12A

38/39

Construction of pMP71 (cont'd)




FIG.12B

FIG.13

1	CGTTTAGTGA	ACCGTATGGC	GGATGTGTGA	CATACACGAC	GCCAAAAGAT	50
51	TTTGTTCAG	CTCCTGCCAC	CTCCGCTACG	CGAGAGATTA	ACCACCCACG	100
101	ATGGCCGCCA	AAGTGCAATG	TGATATTGAG	GCTGACAGCC	CATTCAATCAA	150
151	GTCTTTTGCAG	AAGGCATTTT	CGTCGTTTCA	GGTGGAGTCA	TTGCAGGTCA	200
201	CACCAAATGA	CCATGCAAAT	GCCAGAGCAT	TTTCGCACCT	GGCTACCAAA	250
251	TTGATCGAGC	AGGAGACTGA	CAAAGACACA	CTCATCTTGG	AT	292

39/39

Docket No.
1038-1030 MIS:jb

Declaration and Power of Attorney For Patent Application

English Language Declaration



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ALPHAVIRUS VECTORS

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on November 13, 1998 as United States Application No. or PCT International Application Number PCT/CA98/01065 , and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Michael I. Stewart (24,973)

Send Correspondence to: Sim & McBurney
6th Floor, 330 University Avenue
Toronto, Ontario
Canada, M5G 1R7.

Direct Telephone Calls to: (name and telephone number)
(416) 595-1155

Full name of sole or first inventor

Mark Parrington

Sole or first inventor's signature

Mark Parrington

Date

June 12, 2000

Residence

Bradford, Ontario, Canada *CAX*

Citizenship

Canadian ✓

Post Office Address

45 Martin Street, Bradford, Ontario, Canada, L3Z 1Z4.

Full name of second inventor, if any

Michel H. Klein

Second inventor's signature

Michel H. Klein

Date

July 25, 2000

Residence

Toronto, Ontario, Canada *CAX*

Citizenship

Canadian ✓

Post Office Address

16 Munro Boulevard, Toronto, Ontario, Canada, M2P 1B9.

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/065,793 ✓

(Application Serial No.)

November 14, 1997 ✓

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/CA98/01065

(Application Serial No.)

November 13, 1998

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.